Chemotherapy-Induced Cardiomyopathy in the Elderly

Abstract The older population is preferentially afflicted by cancer and is vulnerable to chemotherapy-related side effects including cardiotoxicity. Unfortunately, this high-risk group is underrepresented in clinical trials and as such there is little guidance for risk assessment and management. In this review, we focus on the commonly used chemotherapeutic agents and their deleterious cardiovascular effects, particularly in the elderly.
Source: Current Cardiovascular Risk Reports - Category: Cardiology Source Type: research

Related Links:

We present the case of a 75-year-old man with severe nonischemic cardiomyopathy on a LifeVest who was found to have a transverse colonic mass with widespread hepatic metastatic disease and was subsequently found to have BRAFV600E-mutant CRC (MSI High/dMMR). After a failed therapy with FOLFOX and pembrolizumab, the patient was started on a regimen of vemurafenib, irinotecan, and cetuximab (VIC) based on the SWOG 1406 trial which had shown improved progression-free survival and response rate for the treatment of BRAFV600E-mutant metastatic CRC. After 40 cycles of VIC, the patient attained complete response and is in remissio...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Basic Res Cardiol. 2021 Oct 20;116(1):61. doi: 10.1007/s00395-021-00902-7.ABSTRACTSystemic effects of advanced cancer impact on the heart leading to cardiac atrophy and functional impairment. Using a murine melanoma cancer model (B16F10 melanoma cells stably transduced with a Ganciclovir (GCV)-inducible suicide gene), the present study analysed the recovery potential of cancer-induced cardiomyopathy with or without use of doxorubicin (Dox). After Dox-free tumor elimination and recovery for 70 ± 5 days, cancer-induced morphologic, functional, metabolic and molecular changes were largely reversible in mice previously ...
Source: Cell Research - Category: Cytology Authors: Source Type: research
In conclusion, the present study supports that some age-related diseases as well as education are causally related to longevity and highlights several new targets for achieving longevity, including management of venous thromboembolism, appropriate intake of sugar, and control of body fat. Our results warrant further studies to elucidate the underlying mechanisms of these reported causal associations. Pol III Inhibition Extends Longevity in Short-Lived Species https://www.fightaging.org/archives/2021/08/pol-iii-inhibition-extends-longevity-in-short-lived-species/ As this paper notes, Pol III is downstream...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Biomed Res Int. 2021 Jul 15;2021:8569921. doi: 10.1155/2021/8569921. eCollection 2021.ABSTRACTDoxorubicin is a cornerstone chemotherapeutic drug widely used to treat various cancers; its dose-dependent cardiomyopathy, however, is one of the leading causes of treatment-associated mortality in cancer survivors. Patients' threshold doses leading to doxorubicin-induced cardiomyopathy (DIC) and heart failure are highly variable, mostly due to genetic variations in individuals' genomes. However, genetic susceptibility to DIC remains largely unidentified. Here, we combined a genetic approach in the zebrafish (Danio rerio) animal ...
Source: Biomed Res - Category: Research Authors: Source Type: research
ilvia Ravera Roberta Tasso Sveva Bollini Cardiovascular side effects are major shortcomings of cancer treatments causing cardiotoxicity and late-onset cardiomyopathy. While doxorubicin (Dox) has been reported as an effective chemotherapy agent, unspecific impairment in cardiomyocyte mitochondria activity has been documented. We demonstrated that the human fetal amniotic fluid-stem cell (hAFS) secretome, namely the secreted paracrine factors within the hAFS-conditioned medium (hAFS-CM), exerts pro-survival effects on Dox-exposed cardiomyocytes. Here, we provide a detailed comparison of the cardioprotective potential...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Abstract: Many antitumoral drugs have been linked to takotsubo cardiomyopathy, with no clear pathogenetic mechanisms. Data about this condition are lacking in literature. The aim of this meta-summary is to summarize the characteristics of patients with antitumoral drug–induced takotsubo cardiomyopathy, described in case reports available in literature. We searched for published case reports in PubMed, Google Scholar, EMBASE, and Scopus from 2009 about stress cardiomyopathy and antiblastic drugs. We selected 41 case reports. All cases underwent chemotherapy/immunotherapy for different types of cancer. The median a...
Source: Journal of Cardiovascular Pharmacology - Category: Cardiology Tags: Review Article Source Type: research
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211027898. doi: 10.1177/15330338211027898.ABSTRACTAlthough Epirubicin (EPI) is a commonly used anthracycline for the treatment of breast cancer in clinic, the serious side effects limit its long-term administration including myelosuppression and cardiomyopathy. Nanomedicines have been widely utilized as drug delivery vehicles to achieve precise targeting of breast cancer cells. Herein, we prepared a DSPE-PEG nanocarrier conjugated a peptide, which targeted the breast cancer overexpression protein Na+/K+ ATPase α1 (NKA-α1). The nanocarrier encapsulated the EPI an...
Source: Technology in Cancer Research and Treatment - Category: Cancer & Oncology Authors: Source Type: research
Arch Biochem Biophys. 2021 Jun 4:108952. doi: 10.1016/j.abb.2021.108952. Online ahead of print.ABSTRACTCancer patients undergoing radiotherapy, chemotherapy, or targeted cancer therapy are exposed to the risk of several side effects because of the heavy production of ROS by ionizing radiation or some chemotherapy drugs. Damages to DNA, mitochondria, membrane and other organelles within normal tissue cells such as cardiomyocytes and endothelial cells lead to the release of some toxins which are associated with triggering inflammatory cells to release several types of cytokines, chemokines, ROS, and RNS. The release of some ...
Source: Archives of Biochemistry and Biophysics - Category: Biochemistry Authors: Source Type: research
Today the pharmacological possibilities of treating cancer are expanding and as a result, life expectancy is increasing against the background of chemotherapy and supportive treatment. In the conditions of successful antitumor treatment, complications associated with its toxic effect on healthy tissues and organs began to come to the fore. Anthracycline cardiomyopathy was the first serious cardiovascular complication to draw the attention of oncologists and cardiologists around the world. Anthracycline drugs such as doxorubicin, epirubicin, idarubicin are still widely used in oncological practice to treat a wide range of s...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Asian Pac J Cancer Prev. 2021 May 1;22(5):1407-1412. doi: 10.31557/APJCP.2021.22.5.1407.ABSTRACTBACKGROUND: Daunorubicine, a type of anthracycline, is a drug commonly used in cancer chemotherapy that increases survival rate but consequently compromises with cardiovascular outcomes in some patients. Thus, preventing the early progression of cardiotoxicity is important to improve the treatment outcome in childhood acute lymhoblastic leukemia (ALL).OBJECTIVE: The present study aimed to identify the risk factors in anthracycline-induced early cardiotoxicity in childhood ALL.METHODS: This retrospective study was conducted by ob...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiomyopathy | Cardiovascular | Chemotherapy | Clinical Trials | Heart